CTXR240816C2000
- 0.07
- -0.03-30.00%
Citius Pharmaceuticals Newsroom
Citius Pharma Analyst Ratings
Citius Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Buy Rating Reaffirmed for Citius Pharmaceuticals Amid Strong Clinical Trial Results and Growth Prospects
Analysts Are Bullish on Top Healthcare Stocks: Citius Pharmaceuticals (CTXR), Actinium Pharmaceuticals (ATNM)
Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Citius Pharmaceuticals (CTXR)
Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV), Citius Pharmaceuticals (CTXR) and Amylyx Pharmaceuticals Inc (AMLX)
Analysts Are Bullish on These Healthcare Stocks: Blueprint Medicines (BPMC), Citius Pharmaceuticals (CTXR)
Citius Pharma Analyst Ratings
Buy Rating for Citius Pharmaceuticals Backed by Resubmission of Lymphir BLA and Potential Orphan Drug Exclusivity
Analysts Offer Insights on Healthcare Companies: Citius Pharmaceuticals (CTXR), Arcus Biosciences (RCUS) and Masimo (MASI)
Strong Buy Rating for Citius Pharmaceuticals Amid Promising Mino-Lok Progress and Strategic Oncology Spinout
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Citius Pharma Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Citius Pharmaceuticals (CTXR), Aprea Therapeutics (APRE)
Citius Pharma Analyst Ratings
Citius Pharmaceuticals (CTXR) Gets a Buy From H.C. Wainwright
Analysts Offer Insights on Healthcare Companies: Citius Pharmaceuticals (CTXR) and Abcam (ABCM)
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI), Tempest Therapeutics (TPST) and Citius Pharmaceuticals (CTXR)
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $6 Price Target